(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.05%.
Century Therapeutics's earnings in 2026 is -$98,819,000.On average, 8 Wall Street analysts forecast IPSC's earnings for 2026 to be -$97,063,598, with the lowest IPSC earnings forecast at -$97,880,784, and the highest IPSC earnings forecast at -$97,245,195. On average, 8 Wall Street analysts forecast IPSC's earnings for 2027 to be -$89,273,086, with the lowest IPSC earnings forecast at -$97,880,784, and the highest IPSC earnings forecast at -$78,177,509.
In 2028, IPSC is forecast to generate -$78,722,300 in earnings, with the lowest earnings forecast at -$80,084,278 and the highest earnings forecast at -$76,270,741.